{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:31:59Z","timestamp":1789821119912,"version":"4.0.1"},"reference-count":199,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Rev. Mol. Med."],"abstract":"<jats:p>Over the past decade, monoclonal antibodies have dramatically impacted the treatment of haematological malignancies, as evidenced by the effect of rituximab on the response rate and survival of patients with follicular and diffuse large B cell non-Hodgkin's lymphoma. Currently, only two monoclonal antibodies \u2013 the anti-CD33 immunotoxin gemtuzumab ozogamicin and the CD52-directed antibody alemtuzumab \u2013 are approved for treatment of relapsed acute myeloid leukaemia in older patients and B cell chronic lymphocytic leukaemia, respectively. Although not approved for such treatment, alemtuzumab is also active against T cell prolymphocytic leukaemia, cutaneous T cell lymphoma and S\u00e9zary syndrome, and adult T cell leukaemia and lymphoma. In addition, rituximab has demonstrated activity against B cell chronic lymphocytic and hairy cell leukaemia. Monoclonal antibodies targeting CD4, CD19, CD20, CD22, CD23, CD25, CD45, CD66 and CD122 are now being studied in the clinic for the treatment of leukaemia. Here, we discuss how these new antibodies have been engineered to reduce immunogenicity and improve antibody targeting and binding. Improved interactions with Fc receptors on immune effector cells can enhance destruction of target cells through antibody-dependent cellular cytotoxicity and complement-mediated cell lysis. The antibodies can also be armed with cellular toxins or radionuclides to enhance the destruction of leukaemia cells.<\/jats:p>","DOI":"10.1017\/s1462399409001215","type":"journal-article","created":{"date-parts":[[2009,9,30]],"date-time":"2009-09-30T10:21:16Z","timestamp":1254306076000},"source":"Crossref","is-referenced-by-count":31,"title":["Antibody-based therapy of leukaemia"],"prefix":"10.1017","volume":"11","author":[{"given":"John C.","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2009,9,1]]},"reference":[{"key":"S1462399409001215_ref198","unstructured":"http:\/\/www.leukemia-lymphoma.org\/all_page.adp?item_id=4702. A registry of ongoing clinical trials including investigational antibodies for treatment of leukemia can be found at:"},{"key":"S1462399409001215_ref197","doi-asserted-by":"publisher","DOI":"10.1517\/14712590802650581"},{"key":"S1462399409001215_ref194","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(06)90003-0"},{"key":"S1462399409001215_ref189","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V88.1.230.230","article-title":"Activation of naive and memory T-cells by interleukin-15","volume":"88","author":"Kanegane","year":"1996","journal-title":"Blood"},{"key":"S1462399409001215_ref186","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.6.1982"},{"key":"S1462399409001215_ref184","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.8.1622"},{"key":"S1462399409001215_ref181","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","article-title":"Radioimmunotherapy of interleukin-2Ra-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac","volume":"86","author":"Waldmann","year":"1995","journal-title":"Blood"},{"key":"S1462399409001215_ref179","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.13.5218"},{"key":"S1462399409001215_ref178","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.052456"},{"key":"S1462399409001215_ref177","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.12.7415"},{"key":"S1462399409001215_ref176","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199901150-00019"},{"key":"S1462399409001215_ref175","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1088"},{"key":"S1462399409001215_ref170","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.suppl_1.i109"},{"key":"S1462399409001215_ref169","doi-asserted-by":"publisher","DOI":"10.1084\/jem.154.5.1455"},{"key":"S1462399409001215_ref168","first-page":"2691","article-title":"Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma","volume":"4","author":"Foss","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"S1462399409001215_ref167","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.8.881"},{"key":"S1462399409001215_ref166","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood.V62.5.988.988","article-title":"Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma","volume":"62","author":"Miller","year":"1983","journal-title":"Blood"},{"key":"S1462399409001215_ref163","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-062877"},{"key":"S1462399409001215_ref162","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","article-title":"Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody","volume":"87","author":"Knox","year":"1996","journal-title":"Blood"},{"key":"S1462399409001215_ref160","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.9.1.7821755"},{"key":"S1462399409001215_ref158","doi-asserted-by":"publisher","DOI":"10.1038\/nri1000"},{"key":"S1462399409001215_ref154","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1254"},{"key":"S1462399409001215_ref153","first-page":"598","article-title":"A Phase I trial of siplizumab in CD2-positive lymphoproliferative disease","volume":"23","author":"O'Mahony","year":"2007","journal-title":"AIDS Research and Human Retroviruses"},{"key":"S1462399409001215_ref150","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02650.x"},{"key":"S1462399409001215_ref149","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141036"},{"key":"S1462399409001215_ref147","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1989.tb00544.x"},{"key":"S1462399409001215_ref142","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood.V106.11.3348.3348","article-title":"A pilot trial of Campath-1H and dose-adjusted EPOCH in CD52-expressing aggressive T-cell malignancies","volume":"106","author":"Janik","year":"2005","journal-title":"Blood"},{"key":"S1462399409001215_ref141","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1182\/blood.V112.11.2010.2010","article-title":"Alemtuzumab (Campath-1H) in patients with HTLV-1-associated adult T-cell leukemia\/lymphoma","volume":"112","author":"Sharma","year":"2008","journal-title":"Blood"},{"key":"S1462399409001215_ref140","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.05.008"},{"key":"S1462399409001215_ref139","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0335"},{"key":"S1462399409001215_ref138","first-page":"6453","article-title":"Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Research"},{"key":"S1462399409001215_ref136","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00143.x"},{"key":"S1462399409001215_ref135","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2802"},{"key":"S1462399409001215_ref134","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.205"},{"key":"S1462399409001215_ref131","doi-asserted-by":"publisher","DOI":"10.1080\/15476910802129661"},{"key":"S1462399409001215_ref129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.021"},{"key":"S1462399409001215_ref128","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11871"},{"key":"S1462399409001215_ref127","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V112.11.2095.2095","article-title":"CFAR, an active frontline regimen for high-risk patients with CLL including those with del 17p","volume":"112","author":"Wierda","year":"2008","journal-title":"Blood"},{"key":"S1462399409001215_ref124","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9098"},{"key":"S1462399409001215_ref123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0159"},{"key":"S1462399409001215_ref121","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11551"},{"key":"S1462399409001215_ref120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.119"},{"key":"S1462399409001215_ref116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.03.024"},{"key":"S1462399409001215_ref115","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood.V62.4.873.873","article-title":"Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement","volume":"62","author":"Hale","year":"1983","journal-title":"Blood"},{"key":"S1462399409001215_ref111","first-page":"675","article-title":"Technology evaluation: lumiliximab, Biogen Idec","volume":"6","author":"Reichert","year":"2004","journal-title":"Current Opinion in Molecular Therapeutics"},{"key":"S1462399409001215_ref108","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404866"},{"key":"S1462399409001215_ref107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2466"},{"key":"S1462399409001215_ref106","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1939"},{"key":"S1462399409001215_ref103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3528"},{"key":"S1462399409001215_ref102","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22342"},{"key":"S1462399409001215_ref101","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0294"},{"key":"S1462399409001215_ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2006.05.007"},{"key":"S1462399409001215_ref99","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/hyb.1994.13.469","article-title":"Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma","volume":"13","author":"Leung","year":"1994","journal-title":"Hybridoma"},{"key":"S1462399409001215_ref151","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.03.018"},{"key":"S1462399409001215_ref97","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11219"},{"key":"S1462399409001215_ref95","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700914"},{"key":"S1462399409001215_ref92","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2268"},{"key":"S1462399409001215_ref91","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.10.5588"},{"key":"S1462399409001215_ref90","doi-asserted-by":"publisher","DOI":"10.1126\/science.1373518"},{"key":"S1462399409001215_ref89","first-page":"1220","article-title":"Prognostic value of immunophenotyping in acute myeloid leukemia","volume":"84","author":"Bradstock","year":"1994","journal-title":"Australian Leukaemia Study Group. Blood"},{"key":"S1462399409001215_ref84","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V110.11.645.645","article-title":"Interim results of a phase I\/II study of ocrelizumab, a new humanised anti-CD20 antibody in patients with relapsed\/refractory follicular non-Hodgkin's lymphoma","volume":"110","author":"Morschhauser","year":"2007","journal-title":"Blood"},{"key":"S1462399409001215_ref81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-111781"},{"key":"S1462399409001215_ref80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117671"},{"key":"S1462399409001215_ref79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0039"},{"key":"S1462399409001215_ref78","first-page":"294","article-title":"Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders","volume":"10","author":"Robak","year":"2008","journal-title":"Current Opinion in Molecular Therapeutics"},{"key":"S1462399409001215_ref77","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"S1462399409001215_ref75","first-page":"1046","article-title":"Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia","volume":"86","author":"Lauria","year":"2001","journal-title":"Haematologica"},{"key":"S1462399409001215_ref74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2619"},{"key":"S1462399409001215_ref187","first-page":"529","article-title":"IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances","volume":"25","author":"Shanmugham","year":"2006","journal-title":"Journal of Experimental and Clinical Cancer Research"},{"key":"S1462399409001215_ref72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0796"},{"key":"S1462399409001215_ref66","doi-asserted-by":"publisher","DOI":"10.1007\/BF02780529"},{"key":"S1462399409001215_ref65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1999.tb01725.x"},{"key":"S1462399409001215_ref63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"S1462399409001215_ref62","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"S1462399409001215_ref61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"S1462399409001215_ref60","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"S1462399409001215_ref146","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"S1462399409001215_ref59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1038"},{"key":"S1462399409001215_ref58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2548"},{"key":"S1462399409001215_ref56","doi-asserted-by":"crossref","unstructured":"56 Clynes R.A. , Towers T.L. , Presta L.G. and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nature Mediane 6, 443-446","DOI":"10.1038\/74704"},{"key":"S1462399409001215_ref54","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"S1462399409001215_ref53","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"S1462399409001215_ref51","first-page":"17","article-title":"CD20: a gene in search of a function","volume":"27","author":"Riley","year":"2000","journal-title":"Seminars in Oncology"},{"key":"S1462399409001215_ref49","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318053ed8e"},{"key":"S1462399409001215_ref48","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.246"},{"key":"S1462399409001215_ref47","doi-asserted-by":"publisher","DOI":"10.1046\/j.0902-4441.2003.00184.x"},{"key":"S1462399409001215_ref46","doi-asserted-by":"publisher","DOI":"10.1038\/nm1483"},{"key":"S1462399409001215_ref44","first-page":"285","article-title":"Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study","volume":"91","author":"Zenz","year":"2006","journal-title":"Haematologica"},{"key":"S1462399409001215_ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05663.x"},{"key":"S1462399409001215_ref40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2317"},{"key":"S1462399409001215_ref39","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V94.4.1237","article-title":"Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome","volume":"94","author":"Matthews","year":"1999","journal-title":"Blood"},{"key":"S1462399409001215_ref37","first-page":"1935","article-title":"Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia","volume":"40","author":"Sgouros","year":"1999","journal-title":"Journal of Nuclear Medicine"},{"key":"S1462399409001215_ref36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.2.294"},{"key":"S1462399409001215_ref35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.133"},{"key":"S1462399409001215_ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07153.x"},{"key":"S1462399409001215_ref33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403350"},{"key":"S1462399409001215_ref32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.988"},{"key":"S1462399409001215_ref31","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22524"},{"key":"S1462399409001215_ref76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0014"},{"key":"S1462399409001215_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.02.005"},{"key":"S1462399409001215_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.04.011"},{"key":"S1462399409001215_ref27","first-page":"950","article-title":"Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups","volume":"89","author":"Amadori","year":"2004","journal-title":"Haematologica"},{"key":"S1462399409001215_ref26","doi-asserted-by":"crossref","unstructured":"26 Tsimberidou, A.M. et al. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemotherapy and Pharmacology 52, 449-452","DOI":"10.1007\/s00280-003-0671-3"},{"key":"S1462399409001215_ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1620"},{"key":"S1462399409001215_ref23","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"S1462399409001215_ref22","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122012751"},{"key":"S1462399409001215_ref21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401851"},{"key":"S1462399409001215_ref18","doi-asserted-by":"publisher","DOI":"10.1021\/bc0100206"},{"key":"S1462399409001215_ref16","doi-asserted-by":"publisher","DOI":"10.1042\/BST0361467"},{"key":"S1462399409001215_ref15","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood.V85.8.2005.bloodjournal8582005","article-title":"Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules","volume":"85","author":"Freeman","year":"1995","journal-title":"Blood"},{"key":"S1462399409001215_ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"S1462399409001215_ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"S1462399409001215_ref10","doi-asserted-by":"publisher","DOI":"10.1080\/10428190210178"},{"key":"S1462399409001215_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02588.x"},{"key":"S1462399409001215_ref8","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-73259-4_4"},{"key":"S1462399409001215_ref7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-73259-4_1"},{"key":"S1462399409001215_ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00601.x"},{"key":"S1462399409001215_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.05.013"},{"key":"S1462399409001215_ref2","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0"},{"key":"S1462399409001215_ref1","doi-asserted-by":"crossref","unstructured":"1 Ehrlich P. (1899\u20131900) Croonian Lecture: On immunity with special reference to cell life Proceedings of the Royal Society of London 66, 424-448","DOI":"10.1098\/rspl.1899.0121"},{"key":"S1462399409001215_ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2153"},{"key":"S1462399409001215_ref114","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.11.6088"},{"key":"S1462399409001215_ref70","doi-asserted-by":"publisher","DOI":"10.1080\/10428190210178"},{"key":"S1462399409001215_ref148","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830210311"},{"key":"S1462399409001215_ref156","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000234905.56926.7f"},{"key":"S1462399409001215_ref71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1258"},{"key":"S1462399409001215_ref98","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02752.x"},{"key":"S1462399409001215_ref87","doi-asserted-by":"publisher","DOI":"10.1038\/nri2019"},{"key":"S1462399409001215_ref180","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","article-title":"The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia","volume":"82","author":"Waldmann","year":"1993","journal-title":"Blood"},{"key":"S1462399409001215_ref193","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509575103"},{"key":"S1462399409001215_ref109","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60776-2"},{"key":"S1462399409001215_ref118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1567"},{"key":"S1462399409001215_ref4","doi-asserted-by":"publisher","DOI":"10.1007\/BF02906136"},{"key":"S1462399409001215_ref144","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"S1462399409001215_ref171","doi-asserted-by":"publisher","DOI":"10.1126\/science.3008337"},{"key":"S1462399409001215_ref83","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.4049\/jimmunol.139.10.3521","article-title":"Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity","volume":"139","author":"Liu","year":"1987","journal-title":"Journal of Immunology"},{"key":"S1462399409001215_ref105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107263450402"},{"key":"S1462399409001215_ref143","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"S1462399409001215_ref30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9764"},{"key":"S1462399409001215_ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"key":"S1462399409001215_ref164","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1148"},{"key":"S1462399409001215_ref183","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood.V83.2.426.426","article-title":"Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma","volume":"83","author":"Kreitman","year":"1994","journal-title":"Blood"},{"key":"S1462399409001215_ref110","doi-asserted-by":"publisher","DOI":"10.3109\/08830189709045705"},{"key":"S1462399409001215_ref57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"S1462399409001215_ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.3197"},{"key":"S1462399409001215_ref191","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.5332"},{"key":"S1462399409001215_ref152","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3601"},{"key":"S1462399409001215_ref190","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4049\/jimmunol.158.1.452","article-title":"Humanized antibodies against the alpha-chain of the IL-2 receptor and against the \u03b2-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases","volume":"158","author":"Guex-Crosier","year":"1997","journal-title":"Journal of Immunology"},{"key":"S1462399409001215_ref67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.027"},{"key":"S1462399409001215_ref122","first-page":"410","article-title":"A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia","volume":"90","author":"Cortelezzi","year":"2005","journal-title":"Haematologica"},{"key":"S1462399409001215_ref132","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2667"},{"key":"S1462399409001215_ref52","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V83.5.1390.1390","article-title":"Retention of B-cell-specific monoclonal antibodies by human lymphoma cells","volume":"83","author":"Press","year":"1994","journal-title":"Blood"},{"key":"S1462399409001215_ref55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-124487"},{"key":"S1462399409001215_ref93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-182048"},{"key":"S1462399409001215_ref68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"S1462399409001215_ref185","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.24.9694"},{"key":"S1462399409001215_ref69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"S1462399409001215_ref155","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.07.015"},{"key":"S1462399409001215_ref195","doi-asserted-by":"publisher","DOI":"10.1080\/15476910802129661"},{"key":"S1462399409001215_ref50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110005"},{"key":"S1462399409001215_ref157","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404731"},{"key":"S1462399409001215_ref188","doi-asserted-by":"publisher","DOI":"10.1038\/nri1901"},{"key":"S1462399409001215_ref199","unstructured":"http:\/\/www.clinicaltrials.gov."},{"key":"S1462399409001215_ref86","doi-asserted-by":"crossref","unstructured":"86 Morschhauser F. (2007) Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I\/II results. J Clin Oncol, ASCO Annual Meeting Proceedings 25, 8032 [Abstract]","DOI":"10.1200\/jco.2007.25.18_suppl.8032"},{"key":"S1462399409001215_ref161","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.V77.1.20.20","article-title":"Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides","volume":"77","author":"Knox","year":"1991","journal-title":"Blood"},{"key":"S1462399409001215_ref17","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.V67.4.1048.1048","article-title":"Expression of normal myeloid-associated antigens by acute leukemia cells","volume":"67","author":"Dinndorf","year":"1986","journal-title":"Blood"},{"key":"S1462399409001215_ref174","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10029"},{"key":"S1462399409001215_ref137","doi-asserted-by":"crossref","unstructured":"137 Alinari L. , Geskin L. , Grady T. , Baiocchi R.A. , Bechtel M.A. and Porcu P. (2008) Subcutaneous alemtuzumab for S\u00e9zary syndrome in the very elderly Leukemia Research 32, 1299-1303","DOI":"10.1016\/j.leukres.2007.11.009"},{"key":"S1462399409001215_ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-1106-9"},{"key":"S1462399409001215_ref73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4459"},{"key":"S1462399409001215_ref82","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood.V112.11.328.328","article-title":"Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: Results from the planned interim analysis of an international pivotal trial","volume":"112","author":"Osterborg","year":"2008","journal-title":"Blood"},{"key":"S1462399409001215_ref19","doi-asserted-by":"publisher","DOI":"10.1126\/science.3240341"},{"key":"S1462399409001215_ref88","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood.V77.10.2242.2242","article-title":"Prognostic value of lymphocyte surface markers in acute myeloid leukemia","volume":"77","author":"Ball","year":"1991","journal-title":"Blood"},{"key":"S1462399409001215_ref24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21326"},{"key":"S1462399409001215_ref119","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"S1462399409001215_ref41","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830261218"},{"key":"S1462399409001215_ref182","unstructured":"182 Morris J.C. (2003) A Phase I trial of humanized anti-Tac (daclizumab) for the treatment of human T-cell lymphotrophic virus type-1-associated leukemia\/lymphoma. Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting Proceedings 22, 695 [Abstract]"},{"key":"S1462399409001215_ref130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3729"},{"key":"S1462399409001215_ref112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-082024"},{"key":"S1462399409001215_ref196","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200923010-00001"},{"key":"S1462399409001215_ref42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.565"},{"key":"S1462399409001215_ref145","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.15.1240"},{"key":"S1462399409001215_ref133","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1721"},{"key":"S1462399409001215_ref126","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2245"},{"key":"S1462399409001215_ref125","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.9950"},{"key":"S1462399409001215_ref113","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1463"},{"key":"S1462399409001215_ref159","first-page":"382","article-title":"Therapy with OKT3 monoclonal antibody in refractory T-cell acute lymphoblastic leukemia induces interleukin-2 responsiveness","volume":"9","author":"Gramatzki","year":"1995","journal-title":"Leukemia"},{"key":"S1462399409001215_ref64","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008389119525"},{"key":"S1462399409001215_ref94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.748"},{"key":"S1462399409001215_ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23655"},{"key":"S1462399409001215_ref104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.437"},{"key":"S1462399409001215_ref192","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.57.5.763"},{"key":"S1462399409001215_ref96","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(00)00524-5"},{"key":"S1462399409001215_ref172","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4049\/jimmunol.126.4.1393","article-title":"A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells","volume":"126","author":"Uchiyama","year":"1981","journal-title":"Journal of Immunology"},{"key":"S1462399409001215_ref117","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90588-0"},{"key":"S1462399409001215_ref38","doi-asserted-by":"publisher","DOI":"10.1038\/nri1530"},{"key":"S1462399409001215_ref85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0493"},{"key":"S1462399409001215_ref173","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.4049\/jimmunol.126.4.1398","article-title":"A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells. II. Expression of Tac antigen on activated cytotoxic killer T-cells, suppressor cells, and on one of two types of helper T-cells","volume":"126","author":"Uchiyama","year":"1981","journal-title":"Journal of Immunology"},{"key":"S1462399409001215_ref165","first-page":"347","article-title":"CD5 signal transduction: Positive or negative modulation of antigen receptor signaling","volume":"20","author":"Lozano","year":"2000","journal-title":"Critical Reviews in Immunology"}],"container-title":["Expert Reviews in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1462399409001215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T23:47:20Z","timestamp":1685144840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1462399409001215\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,1]]},"references-count":199,"alternative-id":["S1462399409001215"],"URL":"https:\/\/doi.org\/10.1017\/s1462399409001215","relation":{},"ISSN":["1462-3994"],"issn-type":[{"value":"1462-3994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,1]]},"article-number":"e29"}}